Vertex to start Phase II trial for investigational Oral HCV protease inhibitor, FDA grants Fast Track designation.
The 28-day study will evaluate the safety, tolerability and pharmacodynamics of VX-950 when combined with pegylated interferon and ribavirin, two existing approved treatments for HCV infection. Vertex says this is the first clinical study of VX-950 to be initiated under an open investigational new drug (IND) application with the FDA and marks the beginning of a broad Phase II clinical development program planned for the drug that will evaluate the compound in multiple clinical studies in 2006, including a three-month study in more than 200 treatment-naive patients.
Vertex reports it expects to obtain 28-day results from the initial Phase II study in the first quarter of 2006. Following completion of the initial phase, patients will receive the standard of care. In early 2006, the company expects to initiate a three-month Phase II clinical study in more than 200 treatment-naive patients. A major object of the study, in addition to an evaluation of safety, will be to measure HCV RNA at the end of treatment and post-treatment as a measure for sustained viral response, potentially enabling a decision to move to Phase III clinical study of RX-950.
Contact: Lynne Brum, - (617) 444-6414, Web site: www.vrtx.com
|Printer friendly Cite/link Email Feedback|
|Comment:||Vertex to start Phase II trial for investigational Oral HCV protease inhibitor, FDA grants Fast Track designation.|
|Date:||Dec 15, 2005|
|Previous Article:||FDA approves first test to screen WNV in organ, tissue, cell, blood donors; will be marketed by Chiron.|
|Next Article:||FDA warns MS patients not to use Campath.|